Navigation Links
Calls to combat deafness after chemotherapy

The Royal National Institute for Deaf people (RNID) has asked drug companies to find ways of reducing the occurrence of deafness among cancer patients who survive chemotherapy. //

The Institute is looking mainly at the effects of the anti-tumor agent cisplatin, which has been successfully used to combat a variety of cancers in adults as well as children. Cisplatin is a platinum-based chemotherapy, which has successfully cured 30 percent of cancers in children and about 25 percent of adult cancers. But it has a major flaw in that it causes tinnitus or ringing in the ears. RNID commercial research manager, Munna Vio said, "Our research indicates that if a suitable drug was approved that effectively protected against hearing loss, but did not interfere with chemotherapy, oncologists would use it across the board for all cancers treated with cisplatin. Thousands of survivors are being left with unnecessary hearing damage."

Drug companies say that such a drug, which blocks the unwanted effects of chemotherapy, is already available. Penelope Brock, a leading British oncologist has also added her voice to this cause, "Permanent side-effects are the most damaging, and hearing loss is one which affects everyday life and development." She feels that with adequate incentive an otoprotectant drug could be on the market within two years.


'"/>




Page: 1

Related medicine news :

1. WHO Calls For Greater Emphasis On Combating AIDS
2. PCT Calls Upon Doctor To Delay Surgeries
3. UN Calls For More Funds For Earthquake Affected
4. MP Calls For Ban On Aspartame
5. Scientist Calls Upon Media To Retract His Work
6. CMHA Calls For Better Trained Police For Dealing With The Mentally Ill
7. US Government Calls For Better Drug Supplies
8. Report Calls For Better Implementation Of Last Wishes of Terminally Ill
9. Mixed Orientation Marriages Calls for Deeper Understanding
10. Rare Sexual Syndrome In Women Calls For More Research
11. Bihar CM Calls For Concerted Efforts To Tackle HIV/AIDS Menace

Post Your Comments:
(Date:12/3/2009)...Newswire/ -- An exciting treatment gaining accepta...telet-rich plasma therapy (PRP), is showing strong...nt procedures, according to a prominent dental res...ology . ,, James Rutkowski, DMD, PhD, reporte...merican Academy of Implant Dentistry that platelet...
(Date:12/3/2009)...new cases created by a single case of H1N1 influen...ccination, social distancing and the use of antivi...he virus, suggests an epidemiological modelling st...7 reported in CMAJ ( Canadian Medical Associat... at data from laboratory-confirmed cases of H1N1 b...
(Date:12/3/2009)...i World Medical, a leading global healthcare compa...ce, announced that international medical quality a...cal Quality Advisory Board (MQAB). , ... –- Satori World Medical, a leading global h...ical travel space, announced that international me...
(Date:12/3/2009)...idue in those who rise and smoke, , , T...cigarette first thing in the morning? If so, take ... smoke inhale more nicotine than other smokers. ,... the researchers said he thinks it could be a sign...drags on their cigarettes. And that, he said, coul...
(Date:12/3/2009)...c. 3 To help children better under...o prevent contracting all forms of influenza, a ne...called Molly and the Flu . ,, The DVD was crea...er (ENAHEC), which is part of the Area Health Educ...tes. ,, The U.S. Centers for Disease Control an...
Breaking Medicine News(10 mins):Health News:Platelet-rich Plasma Enhances Bone and Tissue Growth for Dental Implants 2Health News:Vaccination, antivirals and social distancing may blunt impact of H1N1 influenza 2Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 2Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 3Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 4Health News:Early Morning Smokers May Be More Dependent on Nicotine 2Health News:New Animated DVD Helps Children to Better Understand and Prevent Contracting the Flu 2
... from Chongqing Bureau of Health, BLOOMINGTON, Mi...Education is hosting the first major medical,deleg...a. During their,three-month stay, the physicians w..."We,re honored that the Chongqing Bureau of Health...
...nchronized Slides at 5pm Today, LAWRENCE, Mass., ...leading manufacturer of innovative dialysis produc...irst quarter ended March 31,2008., Revenues for t...venues in the in-center market, from the Company,s...
...eart failure in those with Duchenne muscular dystr...- Patients with Duchenne muscular dystrophy often ...t or delay the onset of this condition, a new Cana...compound called cGMP, which relaxes smooth muscle....
...er influences are limiting the growth ..., May 12 Aon Corporation (NYSE: AOC ),the leadin...g services,today released an analysis of liability...Logo: http://www.newscom.com/cgi-bin/prnh/2004121...
...swire-FirstCall/ -- Tianyin,Pharmaceutical, Co., I...d,supplier of modernized traditional Chinese medic...ed that the Company will present at Roth Third,Ann... Guoqing, Jiang, Tianyin,s Chairman and CEO, Mr. A...
...th,Services, Inc. (Nasdaq: GTIV ), the nation,s l...ces, announced today that it is scheduled to,prese...21, 2008 at the 2008,Citi Investment Research Glob..., http://investors.gentiva.com/events.cfm to regi...
Other Medicine News:Health News:First Major Chinese Medical Delegation Visits Minnesota 2Health News:NxStage Medical Reports First Quarter 2008 Results 2Health News:NxStage Medical Reports First Quarter 2008 Results 3Health News:NxStage Medical Reports First Quarter 2008 Results 4Health News:NxStage Medical Reports First Quarter 2008 Results 5Health News:NxStage Medical Reports First Quarter 2008 Results 6Health News:NxStage Medical Reports First Quarter 2008 Results 7Health News:NxStage Medical Reports First Quarter 2008 Results 8Health News:NxStage Medical Reports First Quarter 2008 Results 9Health News:NxStage Medical Reports First Quarter 2008 Results 10Health News:NxStage Medical Reports First Quarter 2008 Results 11Health News:Viagra May Protect Hearts of Some Muscular Dystrophy Patients 2Health News:Aon Study Finds Stability in Nationwide Liability Costs in the Long Term Health Care Sector 2Health News:Aon Study Finds Stability in Nationwide Liability Costs in the Long Term Health Care Sector 3Health News:Tianyin Pharmaceutical to Present at Roth Third Annual China Discovery Tour in Beijing on May 20, 2008 at 12:40 p.m. Beijing Time 2Health News:Gentiva(R) Health Services to Present May 21 at 2008 Citi Investment Research Global Health Care Conference in New York 2Health News:Gentiva(R) Health Services to Present May 21 at 2008 Citi Investment Research Global Health Care Conference in New York 3
(Date:12/3/2009)... Stryker Corporation (NY...ctors has authorized the Company to repurchase up ...timing and amount of any purchases will be determi...luation of market conditions, stock price and othe...erations. Purchases may be made from time to time...
(Date:12/3/2009)...c. 3 Decision Resources, one of ...cusing on pharmaceutical and healthcare issues, fo...azil will grow from $417 million in 2008 to $834 m...owth rate is attributed to a growing prevalent and...eration antidiabetics such as Merck,s Januvia, Nov...
(Date:12/3/2009)... 3 Honeywell (NYSE: HON ) announ... Pro-Lab Laboratuar Teknolojileri, which will dist...h-purity solvents in Turkey. ,, Burdick & J...ogy and pharmaceutical companies in the drug disco...wth rate of the Turkish pharmaceutical market is e...
Breaking Medicine Technology:Stryker Announces $750 Million Share Repurchase Program and Declares a $0.15 Per Share Quarterly Dividend 2Brazil's Type 2 Diabetes Drug Market Will Grow to $834 Million by 2013 2Brazil's Type 2 Diabetes Drug Market Will Grow to $834 Million by 2013 3Honeywell and Pro-Lab Sign Distribution Agreement for Laboratory Chemicals in Turkey 2Honeywell and Pro-Lab Sign Distribution Agreement for Laboratory Chemicals in Turkey 3Positive trend for diabetic eye health 3B AMD may predict heart disease 3B vision impacts life success 58726 1Positive trend for diabetic eye health 3B AMD may predict heart disease 3B vision impacts life success 58726 2Positive trend for diabetic eye health 3B AMD may predict heart disease 3B vision impacts life success 58726 3Duke Singapore scientists find new way to classify gastric cancers 58725 1Duke Singapore scientists find new way to classify gastric cancers 58725 2New Tools Help Emergency Planners Select Alternate Care Facilities and Transfer Patients During Disasters 58720 1New Tools Help Emergency Planners Select Alternate Care Facilities and Transfer Patients During Disasters 58720 2
...ne 3 Delcath Systems, Inc.,(Nasdaq: DCTH ) annou...thlehem, PA, part of St. Luke,s Hospital & Health ...I clinical trial for the treatment of,inoperable m...s,Percutaneous Hepatic Perfusion (PHP) System for ...r agent melphalan. This Phase III multi-center,stu...
...ed at ASCO Show 26% Partial Response, 63% Clinical... HAYWARD, Calif., June 3 Kosan Biosciences,Incorp...ead Hsp90 inhibitor,tanespimycin, demonstrated a h... when administered in combination with trastuzumab...astatic breast cancer whose disease had,either pro...
Other Medicine Technology:Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Luke's Cancer Center 2Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Luke's Cancer Center 3Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 2Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 3Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 4Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 5Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial 6
PVA, The Personal Vision Assistant
...elco general purpose incubators designed to provid...equired for the most demanding incubation applicat...cubators feature push-button temperature setpoint ...ilt-in over-temperature protection. Equally import...
...ecision Economy Incubators available in five diffe...on; capacities of 1.4 cu. Ft. (39 liters), 2.5 cu....ually important, Precision Economy Incubators comb...ature sensitivity, stability, and uniformity. As a...
40D Large
Medicine Products: